Acquisition Announced
Repligen acquisition of BioLife Solutions
US$1.5bn enterprise value
Announced 22 Jul 2026 · NASDAQ: BLFS · US$31.00 cash and scrip per share · 24% premium
Advisers
BioLife Solutions
Target
- Financial adviser
- Fairness opinion
Repligen
Acquirer
- Financial adviser
- Legal adviser
- Representatives of Perella Weinberg and Goldman Sachs, on behalf of Repligen
- Target
- BioLife Solutions
- Acquirer
- Repligen
- Target based in
- United States
- Buyer based in
- United States
- Equity value
- US$1.6bn
- Sector
- Life Sciences
- Tags
- Life Sciences, Cell Therapy
In the league tables
Similar deals
- Kincell Bio and Cellipont Bioservices merger Sep 2026 · Pharma Services
- DT Cloud Star Acquisition and PrimeGen US merger Feb 2026 · US$1.5bn · Biotech
- BGH Capital acquisition of Aspen Pharmacare Asia Pacific business Jun 2026 · US$1.6bn · Healthcare
- Vista Equity Partners acquisition of Model N Apr 2024 · US$1.3bn · Vertical SaaS
- Tempus AI acquisition of Personalis Jul 2026 · US$1.9bn · Diagnostics
Sources
- 2026 Centerview Partners: Centerview as exclusive financial advisor to BioLife Solutions on their sale to Repligen centerviewpartners.com
- Jul 2026 Perella Weinberg Partners: Financial advisor to Repligen Corporation on its acquisition of BioLife Solutions $1.5B Pending pwpartners.com
- 22 Jul 2026 Press release (EX-99.1, exhibit), Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading sec.gov
- 22 Jul 2026 Press release (EX-99.1, exhibit), Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media Your publication date and time will appear he sec.gov
- 22 Jul 2026 Goodwin Advises Repligen in Acquisition of BioLife Solutions for Approximately $1.5 Billion goodwinlaw.com
- 4 Sep 2026 Definitive merger proxy statement (DEFM14A), BIOLIFE SOLUTIONS INC sec.gov




